PhenoModifier-Variant Detail

Variant "FDFT1:c.201+739A>G"

Search result: 1 record

Variant information

Gene:

FDFT1

Variant:

FDFT1:c.201+739A>G

Genomic location:

chr8:11684463(hg19)

HGVS:

SO Term	RefSeq
protein_coding	NM_001287750.1:c.879+739A>G
protein_coding	NM_001287742.1:c.702+739A>G
protein_coding	NM_001287743.1:c.702+739A>G
protein_coding	NM_001287744.1:c.510+739A>G
protein_coding	NM_001287745.1:c.510+739A>G
protein_coding	NM_001287756.1:c.201+739A>G
protein_coding	NM_004462.4:c.702+739A>G
protein_coding	NM_001287747.1:c.510+739A>G
protein_coding	NM_001287748.1:c.510+739A>G
protein_coding	NM_001287749.1:c.510+739A>G
protein_coding	NM_001287751.1:c.447+739A>G
show all

dbSNP ID:

rs2645424

GWAS trait:

non-alcoholic fatty liver disease,cirrhosis of liver

Modifier statisitcs

Record:

1

Disorder:

1

Reference:

1

Effect type:

Expressivity(1)

Modifier effect:

Altered severity(1)

Detail：

Target disease:

Nonalcoholic Fatty Liver Disease (DOID_0080208)

Effect type:

Expressivity

Modifier effect:

Altered severity

Evidence:

P=6.8×10(-7)

Effect:

Associated with the development NAFLD or disease severity.

Reference:

PMID26740948

Title:

Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population.

Species studied:

Human

Abstract:

We explored potential genetic risk factors implicated in nonalcoholic fatty liver disease (NAFLD) within a Caribbean-Hispanic population in New York City. A total of 316 individuals including 40 subjects with biopsy-proven NAFLD, 24 ethnically matched non-NAFLD controls, and a 252 ethnically mixed random sampling of Bronx County, New York were analyzed. Genotype analysis was performed to determine allelic frequencies of 74 known single-nucleotide polymorphisms (SNPs) associated with NAFLD risk based on previous genome-wide association study (GWAS) and candidate gene studies. Additionally, the entire coding region of PNPLA3, a gene showing the strongest association to NAFLD was subjected to Sanger sequencing. Results suggest that both rare and common DNA variations in PNPLA3 and SAMM50 may be correlated with NAFLD in this small population study, while common DNA variations in CHUK and ERLIN1, may have a protective interaction. Common SNPs in ENPP1 and ABCC2 have suggestive association with fatty liver, but with less compelling significance. In conclusion, Hispanic patients of Caribbean ancestry may have different interactions with NAFLD genetic modifiers; therefore, further investigation with a larger sample size, into this Caribbean-Hispanic population is warranted.